待处理
入排:排除
图源:待检查
Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol 41(23) 3962
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板